INmune Bio is a clinical-stage biotechnology company developing immunotherapies designed to reprogram the innate immune system to treat diseases driven by chronic inflammation and immune dysfunction. The company's lead program is CORDStrom, a mesenchymal stromal cell therapy for recessive dystrophic epidermolysis bullosa, a severe pediatric orphan disease; the company also develops XPro1595, a protein therapeutic targeting neuroinflammation in neurodegenerative diseases such as Alzheimer's disease, and INKmune, a natural killer cell platform for oncology applications. INmune generates value through the development and eventual commercialization of these proprietary immunological therapies, which are intended to address significant unmet medical needs in rare diseases, neuroinflammation, and cancer.